A Comparative Study of Quality of Life in Patients with Low-and Intermediate-risk Prostate Cancer Treated at a Single Institution: Stereotactic Radiotherapy vs. High dose-rate Brachytherapy Monotherapy vs. High dose-rate Brachytherapy Boost
Year: 2017
Type: dissertation
Study design: Observational Study
Abstract: This retrospective cohort analysis aims to compare health-related quality of life (HRQoL) deterioration at 12 months in 648 low-and intermediate-risk prostate cancer (PCa) patients treated with three radiation strategies: stereotactic ablative radiation therapy (SABR), high dose-rate brachytherapy (HDR) monotherapy and HDR boost. Urinary, bowel and sexual HRQoL were prospectively measured at baseline and 12 months using the Expanded Prostate Index Composite (EPIC). A minimally important difference (MID) was defined as a deterioration of HRQoL scores at 12 months compared to baseline â Ľ 0.5 standard deviation of baseline score. Univariate and multivariable logistic regression analyses using generalized estimating equations were used to compare the proportion of patients having MID between groups. SABR and HDR monotherapy were associated with less deterioration in the urinary (OR:0.543, 95%CI:0.320-0.922, p-value=0.024, OR: 0.468, 95%CI:0.432-0.507, p-value
Source: TSpace (University of Toronto)
Author: Joelle Helou
Language: English
Subfield: Urology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2796582355